
    
      The primary objective of this study is to determine the efficacy & toxicity of combined
      docetaxel & capecitabine as primary chemotherapy for subjects with stage II-III breast
      cancer.Subjects will be randomized into one of two groups: Docetaxel followed by four cycles
      of docetaxel & capecitabine vs. capecitabine followed by four cycles of docetaxel and
      capecitabine.
    
  